UK markets close in 17 minutes
  • FTSE 100

    7,156.56
    -155.76 (-2.13%)
     
  • FTSE 250

    18,576.44
    -462.35 (-2.43%)
     
  • AIM

    874.73
    -18.59 (-2.08%)
     
  • GBP/EUR

    1.1626
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2148
    +0.0026 (+0.22%)
     
  • BTC-GBP

    15,751.57
    -872.59 (-5.25%)
     
  • CMC Crypto 200

    409.69
    -21.77 (-5.05%)
     
  • S&P 500

    3,773.51
    -45.32 (-1.19%)
     
  • DOW

    30,682.15
    -347.16 (-1.12%)
     
  • CRUDE OIL

    105.70
    -4.08 (-3.72%)
     
  • GOLD FUTURES

    1,808.40
    -9.10 (-0.50%)
     
  • NIKKEI 225

    26,393.04
    -411.56 (-1.54%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,734.40
    -268.95 (-2.07%)
     
  • CAC 40

    5,899.97
    -131.51 (-2.18%)
     

Insights on the Biosimulation Global Market to 2026 - Featuring Certara, Evidera and Gendata Among Others

·8-min read

Dublin, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The "Biosimulation Market Research Report by Product & Service, Delivery Model, End-user, Application, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Biosimulation Market size was estimated at USD 2,112.80 million in 2020, is expected to reach USD 2,461.84 million in 2021, and projected to grow at a CAGR of 16.85% reaching USD 5,380.45 million by 2026.

Market Statistics

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage

This research report categorizes the Biosimulation to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Product & Service, the market was studied across Services and Software. The Services is further studied across Contract Services and In-house Services. The Software is further studied across Molecular Modeling and Simulation Software, Pbpk Modeling and Simulation Software, Pk/Pd Modeling and Simulation Software, Toxicity Prediction Software, and Trial Design Software.

  • Based on Delivery Model, the market was studied across Ownership Models and Subscription Models.

  • Based on End-user, the market was studied across Contract Research Organizations, Pharmaceutical And Biotechnology Companies, Regulatory Authorities, and Research Institutes.

  • Based on Application, the market was studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across Adme/Tox and Pk/Pd. The Drug Discovery is further studied across Lead Identification and Optimization and Target Identification and Validation.

  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimulation Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimulation Market, including Advanced Chemistry Development, Certara, Chemical Computing Group ULC, Dassault Systemes, Evidera, Gendata AG, In silico biosciences, INOSIM Software, Insilico Biotechnology AG, LeadInvent Pharma Inc, Nuventra Pharma Sciences, Physiomics Plc, Rosa & Co. LLC., Schrodinger, Inc., and Simulations Plus.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Biosimulation Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimulation Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimulation Market?
4. What is the competitive strategic window for opportunities in the Global Biosimulation Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimulation Market?
6. What is the market share of the leading vendors in the Global Biosimulation Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimulation Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Potential demand attributed to adaptations of biosimulation in various sectors such as biotechnology
5.2.2. Growing demand associated with application of biosimulation in clinical trials
5.2.3. Rising investments in drug developments and drug testings
5.3. Restraints
5.3.1. Upscaled prices involved in installations and technique developments for biosimulation
5.4. Opportunities
5.4.1. Favorable governmental laws and regulations to implement biosimulation
5.4.2. Increasing investments in research and development for utilization of biosimulation
5.5. Challenges
5.5.1. Lack of awareness coupled with scarcity of professionals for research and development

6. Biosimulation Market, by Product & Service
6.1. Introduction
6.2. Services
6.2.1. Contract Services
6.2.2. In-house Services
6.3. Software
6.3.1. Molecular Modeling and Simulation Software
6.3.2. Pbpk Modeling and Simulation Software
6.3.3. Pk/Pd Modeling and Simulation Software
6.3.4. Toxicity Prediction Software
6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model
7.1. Introduction
7.2. Ownership Models
7.3. Subscription Models

8. Biosimulation Market, by End-user
8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical And Biotechnology Companies
8.4. Regulatory Authorities
8.5. Research Institutes

9. Biosimulation Market, by Application
9.1. Introduction
9.2. Drug Development
9.2.1. Clinical Trials
9.2.2. Preclinical Testing
9.2.2.1. Adme/Tox
9.2.2.2. Pk/Pd
9.3. Drug Discovery
9.3.1. Lead Identification and Optimization
9.3.2. Target Identification and Validation

10. Americas Biosimulation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Biosimulation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand

12. Europe, Middle East & Africa Biosimulation Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, by Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Advanced Chemistry Development
14.2. Certara
14.3. Chemical Computing Group ULC
14.4. Dassault Systemes
14.5. Evidera
14.6. Gendata AG
14.7. In silico biosciences
14.8. INOSIM Software
14.9. Insilico Biotechnology AG
14.10. LeadInvent Pharma Inc.
14.11. Nuventra Pharma Sciences
14.12. Physiomics Plc
14.13. Rosa & Co. LLC.
14.14. Schrodinger, Inc.
14.15. Simulations Plus

15. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/vp8bc2

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting